Danisco   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Copenhagen Denmark (1996)
Status: Acquired by DuPont (2011) → now Bristol-Myers Squibb (2001)

Organization Overview

First Clinical Trial
2005
NCT00302302
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Danisco | Danisco/Dupont | Danisco Finland | Danisco France SAS | Danisco Sweeteners Ltd. | Danisco Sweeteners Oy

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Constipation (Phase 2)

Diarrhea (Phase 4)

Digestive System Diseases (Phase 2)

Gastrointestinal Diseases (Phase 2)

Hyperglycemia (Phase 2)

Hypertension (Phase 2)

Influenza, Human (Phase 3)

Insulin Resistance (Phase 2)

Irritable Bowel Syndrome (Phase 4)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Thrombosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 34
  • # of Trial APIs: 18